iRadimed Corporation (NASDAQ:IRMD) Stock Has Consensus Price Target of $120.00 According to Brokerages

Key Points

• Analyst consensus is “Moderate Buy” across six brokerages, with an average 12-month price target of $120 versus the stock’s reported $85.82 price.
• iRadimed exceeded quarterly expectations, reporting $0.46 EPS versus the $0.44 consensus and $20.47 million in revenue versus estimates of $20.35 million.
• The company pays a quarterly dividend of $0.20, or $0.80 annually, representing a 0.9% yield; institutional investors own 92.34% of the stock, while insiders hold 34.60%.

iRadimed Corporation (NASDAQ:IRMD - Get Free Report) has earned an average rating of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $120.00.

Several research firms have issued reports on IRMD. Wall Street Zen lowered iRadimed from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Weiss Ratings raised iRadimed from a "hold (c+)" rating to a "buy (b-)" rating in a report on Friday, October 16th. Finally, Needham & Company LLC started coverage on iRadimed in a report on Tuesday, September 22nd. They issued a "hold" rating on the stock.

Insider Activity at iRadimed

In other news, Director Monty K. Allen sold 1,419 shares of the business's stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total value of $122,615.79. Following the completion of the sale, the director directly owned 19,581 shares of the company's stock, valued at approximately $1,691,994.21. The trade was a 6.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 34.60% of the company's stock.

Hedge Funds Weigh In On iRadimed

Several hedge funds have recently added to or reduced their stakes in IRMD. Integrated Wealth Concepts LLC acquired a new position in iRadimed in the 2nd quarter valued at $28,000. IFP Advisors Inc boosted its holdings in shares of iRadimed by 264.7% in the 2nd quarter. IFP Advisors Inc now owns 569 shares of the medical equipment provider's stock valued at $54,000 after purchasing an additional 413 shares during the last quarter. Global Retirement Partners LLC purchased a new stake in shares of iRadimed during the 2nd quarter valued at $84,000. Inspire Investing LLC acquired a new position in iRadimed in the first quarter valued at $107,000. Finally, State of Wyoming acquired a new stake in iRadimed during the second quarter worth about $130,000. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

iRadimed Trading Down 2.1%

NASDAQ:IRMD opened at $85.82 on Friday. iRadimed has a 12 month low of $75.75 and a 12 month high of $107.90. The company has a 50-day moving average price of $86.02 and a 200-day moving average price of $90.10. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of 47.94 and a beta of 0.91.

iRadimed (NASDAQ:IRMD - Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.02. The business had revenue of $20.47 million during the quarter, compared to analyst estimates of $20.35 million. iRadimed had a return on equity of 23.45% and a net margin of 26.70%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Equities analysts forecast that iRadimed will post 1.98 EPS for the current fiscal year.

iRadimed Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 28th. Shareholders of record on Friday, August 14th were given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, August 14th. iRadimed's payout ratio is currently 44.69%.

About iRadimed

iRadimed Corporation NASDAQ: IRMD develops, manufactures and sells medical devices designed for use during magnetic resonance imaging (MRI) procedures. The company focuses on solutions that allow clinicians to deliver intravenous medications and monitor patients safely while they are in or near an MRI scanner.

Its principal products include the MRidium MRI-compatible infusion pump systems, which are designed to administer intravenous fluids and medications without interfering with MRI operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.